OTCMKTS:PXXLF

Poxel (PXXLF) Stock Price, News & Analysis

$0.70
0.00 (0.00%)
(As of 04/22/2024 ET)
Today's Range
$0.70
$0.70
50-Day Range
$0.55
$0.70
52-Week Range
$0.55
$0.70
Volume
N/A
Average Volume
5 shs
Market Capitalization
$20.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PXXLF stock logo

About Poxel Stock (OTCMKTS:PXXLF)

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

PXXLF Stock Price History

PXXLF Stock News Headlines

Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Best Nintendo Switch Games in 2024
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
10 addictive Android games to play
The best Google Pixel 8 Pro cases in 2024
12 Games Set In Ancient China
Google I/O 2024 to take place May 14
See More Headlines
Receive PXXLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Poxel and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Private households
Sub-Industry
N/A
Current Symbol
OTCMKTS:PXXLF
CIK
N/A
Employees
15
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$710,000.00
Book Value
($0.66) per share

Miscellaneous

Free Float
N/A
Market Cap
$20.27 million
Optionable
Not Optionable
Beta
0.53
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Thomas Kuhn M.B.A.
    Pharm D MBA, Pharm.D., Co-Founder, CEO & Director
  • Dr. Sébastien Bolze Ph.D.
    Pharm D Ph.D., Pharm.D., Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing Operations
  • Dr. Pascale Fouqueray-Grellier M.D.
    Ph.D., Co-Founder and Executive VP of Clinical Development & Regulatory Affairs
  • Dr. Sophie Hallakou-Bozec Ph.D.
    Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication
  • Arthur Rouille
    Investor Relations Officer
  • Mr. Quentin Durand
    Executive VP, Chief Legal Officer & Head of Corporate Social Responsibility
  • Ms. Sylvie Bertrand
    Vice President of Human Resources

PXXLF Stock Analysis - Frequently Asked Questions

How have PXXLF shares performed in 2024?

Poxel's stock was trading at $0.60 at the beginning of 2024. Since then, PXXLF stock has increased by 16.7% and is now trading at $0.70.
View the best growth stocks for 2024 here
.

How do I buy shares of Poxel?

Shares of PXXLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:PXXLF) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners